Biotech Values

[DewDiligence]

Roche’s CT-388 GLP-1/GIP—>18.8% placebo-adjusted weight_loss_at_24wks—good_tolerability:

https://www.globenewswire.com/news-release/2024/05/16/2883079/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-reports-positive-Phase-I-results-for-its-dual-GLP-1-GIP-receptor-agonist-CT-388-in-people-with-obesity.html

CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signalling significantly minimises receptor internalisation and consequent desensitisation, which is expected to lead to prolonged pharmacological activity.

Dosing in the trial in question was weekly by subcutaneous injection.